First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial, PMID: 33485464
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer, PMID: 29355075
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain, PMID: 30134131
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma, PMID: 30124333
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer, PMID: 30110194
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study, PMID: 31345627
Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma, PMID: 30334646
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer, PMID: 29731394
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial, PMID: 32416781
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort, PMID: 31629915
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial, PMID: 32916128
Ipilimumab: an investigational immunotherapy for glioblastoma, PMID: 32945231
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials, PMID: 29370992
First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis, PMID: 30789633
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1, PMID: 33485960
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial, PMID: 32852531
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial, PMID: 32853585
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer, PMID: 32238575
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma, PMID: 28981385
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609, PMID: 31880964
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials, PMID: 32580338
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma, PMID: 29975414
The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature review, PMID: 31348136
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis, PMID: 33239030
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer, PMID: 27458307
Ipilimumab-induced hypophysitis, a single academic center experience, PMID: 31327112
Ipilimumab-Induced Secondary Hypophysitis, PMID: 29624100
Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer, PMID: 32101673
Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer, PMID: 32101672
Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response, PMID: 32414761
Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer, PMID: 31002006
Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter, PMID: 32414760
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab, PMID: 26787752
Ipilimumab for the treatment of metastatic prostate cancer, PMID: 29271259
Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy, PMID: 33189597
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis, PMID: 28495807
Ipilimumab-Induced Sarcoidosis and Thyroiditis, PMID: 28207422
The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis, PMID: 32620130
Ipilimumab induced digital vasculitis, PMID: 29433584
Pemphigus associated with ipilimumab therapy, PMID: 33410503
Ipilimumab-associated cholestatic hepatitis: a case report and literature review, PMID: 28489679
European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma, PMID: 33188050
Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer. Reply, PMID: 32101674
Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma, PMID: 32416774
A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA), PMID: 30871493
Immune Checkpoint Inhibitors-Induced Hepatitis, PMID: 30539511
ANCA-associated vasculitic neuropathy during treatment with ipilimumab, PMID: 31209477
[Alopecia areata under ipilimumab], PMID: 29653853
Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects, PMID: 29303446
Ipilimumab-induced renal granulomatous arteritis: a case report, PMID: 31604452
An evaluation of Nivolumab and ipilimumab for the treatment of resectable stage III melanoma., PMID:40531544
Rapid-Onset Myositis and Myocarditis Following Dual Immune Checkpoint Inhibitor Therapy With Nivolumab and Ipilimumab for Gastric Adenocarcinoma: A Case Report., PMID:40519473
Impaired Overall Survival of Melanoma Patients Due to Antibiotic Use Prior to Immune Checkpoint Inhibitor Therapy: Systematic Review and Meta-Analysis., PMID:40507352
Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data., PMID:40507314
Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database., PMID:40506075
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study., PMID:40505525
NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies., PMID:40502306
Biomarker analysis and treatment dynamics following preoperative ipilimumab plus nivolumab in locally advanced urothelial cancer from the phase 1B NABUCCO study., PMID:40489082
Organ-Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study., PMID:40488227
CTLA-4 blockade in ovarian cancer immunotherapy: Mechanisms and clinical strategies., PMID:40482550
Cost-Utility and Budget Impact Analysis of Immunotherapy for First-Line Treatment of Advanced Kidney Cancer in Latin America: Evidence From Uruguay., PMID:40482312
A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE)., PMID:40475164
Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial., PMID:40474841
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1., PMID:40473108
Immune-mediated enterocolitis is associated with immune checkpoint inhibitors: A pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database., PMID:40465755
Malignant mesothelioma with a novel BAP1 germline frameshift mutation treated with dual immune checkpoint inhibitors: A case report., PMID:40463358
Primary Vaginal Melanoma or Clear Cell Sarcoma: A Difficult Differential Diagnosis., PMID:40462828
Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade., PMID:40460830
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study., PMID:40449497
Clinical Management and Outcomes of Immune-Related Adverse Events During Treatment with Immune Checkpoint Inhibitor Therapies in Melanoma and Renal Cell Carcinoma: A UK Real-World Evidence Study., PMID:40448748
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA., PMID:40446626
Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study., PMID:40446096
The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?, PMID:40433369
Correlation Between Body Mass Index and Clinical Outcomes in Advanced Renal Cell Carcinoma Patients., PMID:40425321
Using liquid biopsies to guide treatment and monitor response in BRAF V600E positive adenocarcinoma of unknown primary., PMID:40425210
Spontaneous Dramatic Regression of Clear Cell Renal Cell Carcinoma After Pazopanib-Induced Severe Systemic Inflammatory Syndrome: A Case Report and Literature Review., PMID:40422519
Multisystem immune-related adverse reactions with immune checkpoint inhibitors., PMID:40421943
Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma., PMID:40416920
Case Report: Acral vasculitis induced by Immune Checkpoint Inhibitors: a case series and literature review., PMID:40416866
The Importance of Timing in Immunotherapy: A Systematic Review., PMID:40416194
Adjuvant Immunotherapy in Microsatellite Instability-High Colon Cancer: A Literature Review on Efficacy, Challenges, and Future Directions., PMID:40415356
Systemic Therapy for Melanoma: What Surgeons Need to Know., PMID:40413004
A treatment-related death predictive score for treatment-naïve advanced non-small cell lung cancer., PMID:40409025
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort., PMID:40402690
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-Risk Melanoma., PMID:40392969
Real-world efficacy and safety of nivolumab and ipilimumab in metastatic renal cell carcinoma: a Polish multicenter study., PMID:40391586
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374
Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study., PMID:40389373
Metabolic tumor volume on 18F-FDG uptake as a negative predictor after ipilimumab plus nivolumab in advanced non-small cell lung cancer., PMID:40386730
Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma., PMID:40382268
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer., PMID:40378356
[Renal injury during combination immunotherapy (ipilimumab + nivolumab) in patients with metastatic renal cell cancer who previously underwent nephrectomy]., PMID:40377638
Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Rechallenge with Temsirolimus and Bevacizumab., PMID:40376550
Association of Sinonasal Symptoms and Disease With Immune Checkpoint Inhibitor Therapy., PMID:40370338
Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Single-Center Experience of Biopsy-Proven Cases., PMID:40364262
Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: a systematic review and network meta-analysis of randomized controlled trials., PMID:40360867
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)., PMID:40360544
An Extremely Rare Case of Immune Checkpoint Inhibitors-Related Hypoparathyroidism and a Critical Literature Review., PMID:40356787
Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies., PMID:40354680
Adverse neurologic events of immune checkpoint inhibitor monotherapy vs. combination therapy for melanoma., PMID:40351833
For research use only. Not for human or drug use.
